Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2024-08-28 DOI:10.3390/curroncol31090370

Han Yin, Fernanda Romero-Hernandez, Amir Ashraf Ganjouei, Jaeyun Jane Wang, Audrey Brown, Kenzo Hirose, Ajay V. Maker, Eric Nakakura, Carlos Corvera, Kimberly S. Kirkwood, Alexander Wilhelm, June S. Peng, Adnan Alseidi, Mohamed A. Adam

{"title":"Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)","authors":"Han Yin, Fernanda Romero-Hernandez, Amir Ashraf Ganjouei, Jaeyun Jane Wang, Audrey Brown, Kenzo Hirose, Ajay V. Maker, Eric Nakakura, Carlos Corvera, Kimberly S. Kirkwood, Alexander Wilhelm, June S. Peng, Adnan Alseidi, Mohamed A. Adam","doi":"10.3390/curroncol31090370","DOIUrl":null,"url":null,"abstract":"Pancreatoblastoma is perceived to be aggressive in adults; however, data are limited due to the rarity of the disease. We benchmarked clinico-pathologic characteristics, outcomes, and survival of adult patients with pancreatoblastoma to a comparable PDAC cohort using the National Cancer Database (NCDB). This study included 301,204 patients: 35 with pancreatoblastoma and 301,169 PDAC patients. Pancreatoblastoma patients were younger than PDAC patients (56 vs. 69 years, p < 0.001). More pancreatoblastoma patients were managed at academic institutions (63.0% vs. 40.7%, p = 0.047). The most frequent primary site was the head and the neck of the pancreas. There were no differences in tumor size (4.2 cm vs. 3.7 cm, p = 0.828), lymph node positivity (14.3% vs. 26.4%, p = 0.103), or metastasis at time of diagnosis (31.4% vs. 46.1%, p = 0.081). The majority of pancreatoblastoma patients underwent resection compared to a minority of PDAC patients (69.7% vs. 15.5%, p < 0.001). Time from diagnosis to surgery was longer for pancreatoblastoma patients (33 vs. 14 days, p = 0.030). Pancreaticoduodenectomy was the most common type of resection in the pancreatoblastoma and PDAC groups (47.8% vs. 67.7%, p = 0.124). Among resected patients, pancreatoblastoma patients were less likely to receive radiation (4.8% vs. 37.0%, p = 0.002), but the use of chemotherapy was similar to PDAC patients (60.9% vs. 70.7%). After matching, median overall survival was longer for pancreatoblastoma than PDAC (59.8 months vs. 15.2 months, p = 0.014).","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31090370","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreatoblastoma is perceived to be aggressive in adults; however, data are limited due to the rarity of the disease. We benchmarked clinico-pathologic characteristics, outcomes, and survival of adult patients with pancreatoblastoma to a comparable PDAC cohort using the National Cancer Database (NCDB). This study included 301,204 patients: 35 with pancreatoblastoma and 301,169 PDAC patients. Pancreatoblastoma patients were younger than PDAC patients (56 vs. 69 years, p < 0.001). More pancreatoblastoma patients were managed at academic institutions (63.0% vs. 40.7%, p = 0.047). The most frequent primary site was the head and the neck of the pancreas. There were no differences in tumor size (4.2 cm vs. 3.7 cm, p = 0.828), lymph node positivity (14.3% vs. 26.4%, p = 0.103), or metastasis at time of diagnosis (31.4% vs. 46.1%, p = 0.081). The majority of pancreatoblastoma patients underwent resection compared to a minority of PDAC patients (69.7% vs. 15.5%, p < 0.001). Time from diagnosis to surgery was longer for pancreatoblastoma patients (33 vs. 14 days, p = 0.030). Pancreaticoduodenectomy was the most common type of resection in the pancreatoblastoma and PDAC groups (47.8% vs. 67.7%, p = 0.124). Among resected patients, pancreatoblastoma patients were less likely to receive radiation (4.8% vs. 37.0%, p = 0.002), but the use of chemotherapy was similar to PDAC patients (60.9% vs. 70.7%). After matching, median overall survival was longer for pancreatoblastoma than PDAC (59.8 months vs. 15.2 months, p = 0.014).

查看原文本刊更多论文

成人胰母细胞瘤：与胰腺导管腺癌 (PDAC) 相比的临床见解和结果

胰腺母细胞瘤在成人中被认为具有侵袭性；然而，由于这种疾病的罕见性，相关数据非常有限。我们利用美国国家癌症数据库（NCDB）将成年胰腺母细胞瘤患者的临床病理特征、预后和存活率与可比的 PDAC 患者队列进行了比较。这项研究包括 301204 名患者：35名胰母细胞瘤患者和301,169名PDAC患者。胰母细胞瘤患者比 PDAC 患者更年轻（56 岁对 69 岁，P < 0.001）。在学术机构接受治疗的胰母细胞瘤患者更多（63.0% 对 40.7%，p = 0.047）。最常见的原发部位是胰腺头部和颈部。诊断时肿瘤大小（4.2 厘米对 3.7 厘米，P = 0.828）、淋巴结阳性率（14.3% 对 26.4%，P = 0.103）或转移率（31.4% 对 46.1%，P = 0.081）均无差异。大多数胰腺母细胞瘤患者接受了切除术，而PDAC患者中只有少数接受了切除术（69.7% vs. 15.5%，p < 0.001）。胰腺母细胞瘤患者从诊断到手术的时间更长（33 天对 14 天，p = 0.030）。在胰腺母细胞瘤组和 PDAC 组中，胰十二指肠切除术是最常见的切除类型（47.8% 对 67.7%，p = 0.124）。在切除的患者中，胰母细胞瘤患者接受放射治疗的可能性较低（4.8% 对 37.0%，p = 0.002），但化疗的使用率与 PDAC 患者相似（60.9% 对 70.7%）。匹配后，胰母细胞瘤患者的中位总生存期长于PDAC患者（59.8个月 vs. 15.2个月，p = 0.014）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.